Syntarga Announces Additional Antibody-Drug Conjugate Collaborations
Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into three additional research collaborations since its March 2010 press release. These latest agreements comprise a second collaboration with one of the two top-15 biopharma companies announced in March and collaborations with a new, undisclosed top-tier biopharma company, and a new, undisclosed mid-size biotechnology company.
ADCs will be evaluated by the Company’s collaborators based on different Syntarga proprietary Linker-Drug chemistries and a variety of collaborator antibodies. Syntarga has generated a strong biological data package for its synthetic Linker-Drug payloads with ADCs against multiple antigen targets, including Her2. The Company believes that more research collaborations with established companies will be started in the near future.
“The steadily increasing number of collaborations with top-tier biopharma companies exemplify the growing interest in Syntarga’s proprietary Linker-Drug technology to empower anticancer antibodies. These relationships help the Company with implementing its strategy to bring ADC products based on its technology into the clinic as soon as feasible.” said Dr. Vincent de Groot, Chief Executive Officer of Syntarga.
About Syntarga BV
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug Conjugate technology and products for the treatment of cancer. The Company’s cutting-edge chemistry capabilities and unique know-how have led to the creation of its antibody empowering Potent Payload Technology. Syntarga is leveraging its proprietary technologies and expertise to generate and commercialize, alone and with partners, a portfolio of next generation Antibody-Drug Conjugate products. For more information about Syntarga, visit its website at www.syntarga.com.